5400 Carillon Point
Building 5000 4th Floor
Mavupharma is a drug discovery and development company focused on novel approaches to selectively targeting the STING pathway, leveraging the innate immune system to treat cancer and infectious diseases. Mavupharma recently completed a $20 million Series A financing led by Frazier Healthcare Partners.
President: Michael Gallatin, Ph.D.
CSO: Greg Dietsch, Ph.D., DABT
COO: Clayton D. Knox, M.D.
3 articles with Mavupharma
The drugs target a protein called STING (stimulator of interferon genes), which plays an important role in the innate immune system, which is the body’s first line of defense against various pathogens.
Mavupharma Selects First Immuno-Oncology Clinical Candidate MAVU-104, an Oral STING Pathway Enhancer
Mavupharma (Mavu) announced today that it has selected its first immuno-oncology clinical development candidate, MAVU-104, a novel innate immune modulator.
The Series A funding will be used primarily to advance Mavu's lead drug candidates into the clinic.